The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients
Scholars, analysts, and companies cannot agree on what Amgen v. Sanofi means for patients, drug makers, and innovation.
USPTO
-
Read more: The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients -
Read more: Don’t Be Too Alarmed by the New SCOTUS Antibody Ruling Don’t Be Too Alarmed by the New SCOTUS Antibody Ruling
SCOTUS revisits enablement, but Amgen v. Sanofi probably won’t transform patent law on its own.
-
Read more: Visualizing the Growing Intersection of Life Sciences and Computing Patents in the US from 1976-2021 Visualizing the Growing Intersection of Life Sciences and Computing Patents in the US from 1976-2021
Mapping the growth of U.S. innovation in the life sciences and computing fields from 1976-2021 through publicly available patent data.
-
Read more: Get Your Story Straight: Patent Office Cracks Down on Inconsistent Statements Made Before the FDA Get Your Story Straight: Patent Office Cracks Down on Inconsistent Statements Made Before the FDA
While it may not seem controversial to promote honesty before the USPTO, a recent Federal Register Notice goes far beyond requiring candor.
-
Read more: Access-to-Medicines Activists Demand Health Justice During COVID-19 Pandemic Access-to-Medicines Activists Demand Health Justice During COVID-19 Pandemic
Activists in the access-to-medicines movement have mobilized to combat the threat of vaccine/therapeutic apartheid during the COVID-19 pandemic.
-
Read more: The Prospects for an IP Waiver Under the TRIPS Agreement The Prospects for an IP Waiver Under the TRIPS Agreement
Going forward, practical solutions should focus on scaling up manufacturing and supply, and improving access and affordability.
-
Read more: The Patent Trial and Appeal Board Again Survives Supreme Court Review The Patent Trial and Appeal Board Again Survives Supreme Court Review
For the generic drug and biosimilar industries, the Supreme Court’s recent decision in United States v. Arthrex, Inc. comes as a relief.
-
Read more: US Support for a WTO Waiver of COVID-19 Intellectual Property – What Does it Mean? US Support for a WTO Waiver of COVID-19 Intellectual Property – What Does it Mean?
An explanation of the WTO waiver of COVID-19 intellectual property, what the U.S. declaration of support means, and likely effects of the waiver.
-
Read more: The Patent Trial and Appeal Board Returns to the Supreme Court The Patent Trial and Appeal Board Returns to the Supreme Court
How the Court decides United States v. Arthrex will have important implications for patent law and for administrative law more generally.